Skip to main content
. 2016 Jan 21;22(3):1160–1171. doi: 10.3748/wjg.v22.i3.1160

Table 1.

Targeted therapies in advanced gastric cancer investigated in clinical trials

Target Drug Study phase Status
HER2 Trastuzumab Phase III Available results[5]
T-DM1 Phase II Ongoing (NCT01702558)
Phase III Ongoing (NCT01641939)
Lapatinib Phase III Available results[32]
Phase III Available results[33]
HER2/HER3 Pertuzumab Phase II Available results[31]
Phase III Ongoing (NCT01774786)
EGFR Cetuximab Phase III Available results[37]
Panitumumab Phase III Available results[38]
Nimotuzumab Phase II1 Available results[39]
Erlotinib Phase II Available results[40]
VEGF Bevacizumab Phase III Available results[52]
VEGFR-2 Ramucirumab Phase III Available results[18]
Phase III Available results[19]
Phase II1 Available results[53]
Phase III Ongoing (NCT02314117)
Apatinib Phase III Available results[54]
PIK3/Akt/mTOR Everolimus Phase III Available results[61]
Phase III Ongoing (NCT01248403)
Phase I Ongoing (NCT01049620)
MK-2206 Phase II Ongoing (NCT01260701)
BYL719 Phase I Ongoing (NCT01613950)
FGFR2 Dovitinib Phase I/II Ongoing (NCT01921673)
Phase II Ongoing (NCT01719549)
AZD4547 Phase II1 Available results[68]
MET Rilotumumab Phase II Available results[73]
Phase III Available results[74]
Phase III Available results[75]
Onartuzumab Phase III Available results[72]
Foretinib Phase II Available results[71]
Tivantinib Phase II Available results[76]
PD-L1 Pembrolizumab Phase Ib Available results[84]
Phase II Ongoing (NCT02335411)
CTLA-4 Tremelimumab Phase I/II Ongoing (NCT02340975)
JAK2 AZD1480 Phase I Ongoing (NCT01219543)
PARP Olaparib Phase III Ongoing (NCT01924533)
1

Randomized phase II trials. HER2: Human epidermal growth factor receptor 2; HER3: Human epidermal growth factor receptor 3; EGFR: Epidermal growth factor receptor; VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor; PIK3CA/AKT/mTOR: Phosphatidylinositol 3-kinase CA/AKT/Mammalian target of rapamycin; FGFR2: Fibroblast growth factor receptor 2; MET: Mesenchymal-epithelial transition; PD-L1: Programmed cell death-ligand 1; JAK2: Janus kinase 2; PARP: Poly (adenosine diphosphate [ADP]–ribose) polymerase.